The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder: prospective randomized trial
Abstract
Bladder outlet obstruction mediated underactive bladder represents a challenging condition in which transurethral resection of prostate did not prove to be a sufficient treatment option. Therefore, this study was conducted to evaluate the effects and adverse effects of Pyridostigmine as a treatment for underactive bladder after transurethral resection of prostate. This prospective, double-blind, randomized controlled study was conducted between May 2024 and November 2024. Sixty-six patients who had benign prostatic hyperplasia with preoperative underactive bladder and eligible for transurethral resection of prostate were randomized into two groups: the Pyridostigmine group, which received Pyridostigmine 120 mg daily for 3 months postoperatively, and the control group, which received placebo postoperatively. Patients were followed-up for 3 months postoperatively to observe symptom changes, urodynamic changes and adverse effects. Patient who received Pyridostigmine showed significant improvement compared to the control group patients regarding IPSS score (p = 0.001), quality of life (p < 0.001), postvoid residual volume (p = 0.002), maximum flow rate (p < 0.001), contractility index (p = 0.001) and postoperative retention incidence (p = 0.005). Mild adverse effects were reported in 23.5% of patients who received Pyridostigmine with no reported serious adverse effects. Pyridostigmine after transurethral resection of prostate in patients with underactive bladder with benign…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.